We recently published our analysis in the journal Cancer, explaining why we believe an trial testing pembrolizumab in this setting – KEYNOTE-A18 – should not change practice.
Regulators and HTA agencies should enforce stricter guidelines to ensure that control arm participants receive adequate post-protocol care.
This is a repeated pattern in industry-sponsored trials. Look at ADAURA and the adjuvant I/0 trials in esophageal and renal cell carcinomas
Thank you for doing this analysis
Regulators and HTA agencies should enforce stricter guidelines to ensure that control arm participants receive adequate post-protocol care.
This is a repeated pattern in industry-sponsored trials. Look at ADAURA and the adjuvant I/0 trials in esophageal and renal cell carcinomas
Thank you for doing this analysis